多西他塞联合顺铂方案化疗对晚期非小细胞肺癌患者外周血淋巴细胞表型的影响

Observation of Changes in Peripheral Lymphocyte Subsets by Flow Cytometry in Patients with Non-small Cell Lung Cancer with Docetaxel Combination with Cisplatin Regimen

目的探讨多西他塞(docetaxel)联合顺铂(CDDP)的治疗方案对晚期非小细胞肺癌患者外周血淋巴细胞表型的影响。方法47例经病理学或细胞学确诊的晚期非小细胞肺癌患者,采用多西他塞25mg/m2,第1、8、15d静脉滴注1h;CDDP25mg/m2,第1～3d静脉滴注;28d为一周期,每例患者至少治疗两个周期。应用流式细胞仪检测CD3+、C04+、CD8+、CDl6+56+、CD19+细胞的百分率。结果晚期非小细胞肺癌患者经多西他塞联合顺铂的治疗方案化疗后CD4+、CD4+/CD8+、CD16+56+较化疗前显著升高(P<0.05);CD3+、CD8+、CD19+化疗前后无显著差异(P>0.05)。结论多西他塞联合顺铂的治疗方案化疗可改善晚期非小细胞肺癌患者机体的免疫功能。

Objective To evaluate the changes in peripheral lymphocyte subsets by flow cytometry of docetaxel combination with cisplatin regimen in patients with advanced non-small cell lung cancer. Methods A total of fortyseven patients with a pathologic diagnosis enrolled in the study were treated with paclitaxe125mg/m^2 infusion for l h on day 1,8,15 and cisplatin 25mg/m^2 infusion on day 1 to 3.It was repeated every 28 days.Every patient must be treated for two cycles then evaluated with the flow cytometry for CD3＋, CD4＋, CD8＋, CD16＋56＋, CD19＋. Results The expressive rates of CD4＋ , CD16＋56＋ and CD4＋/CD8＋ in peripheral blood were higher in post-treatment patients than in pre-treatment samples （P〈0.05）.No evident case of changes of CD3＋、 CD8＋, CD19＋ positive cell percentage were observed after chemotherapy （F〉0.05）.Conclusion Docetaxel combination with cisplatin regumen for advanced non-small cell lung cancer can activate patient＇s immune function.